Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19309669 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | August 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19278180 | LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATION | July 2025 | October 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19060293 | URSOLIC ACID MORPHOLINE SALT | February 2025 | June 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 19027091 | INDANE-, INDENE-, AZAINDANE-, AND AZAINDENE-AMINES AS ACTIVATORS OF SEROTONIN RECEPTORS | January 2025 | January 2026 | Allow | 60 | 2 | 0 | Yes | No |
| 18968148 | COMPOSITIONS AND METHODS FOR MUSCLE REGENERATION USING PROSTAGLANDIN E2 | December 2024 | March 2026 | Abandon | 15 | 2 | 1 | No | No |
| 18955947 | SOLID POLYMORPHS OF A FLNA-BINDING COMPOUND AND ITS HYDROCHLORIDE SALTS | November 2024 | July 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18910781 | URSOLIC ACID MORPHOLINE AND DIETHANOLAMINE SALTS | October 2024 | November 2024 | Allow | 1 | 0 | 0 | Yes | No |
| 18904951 | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles | October 2024 | May 2025 | Allow | 8 | 0 | 1 | No | No |
| 18783734 | PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINE | July 2024 | March 2026 | Allow | 19 | 0 | 0 | Yes | No |
| 18673394 | IONIZABLE LIPIDS | May 2024 | February 2026 | Allow | 20 | 0 | 0 | Yes | No |
| 18670262 | DYE ENHANCED VISUALIZATION OF CATARACT SURGERY | May 2024 | December 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18652849 | NOVEL POTASSIUM CHANNEL INHIBITORS | May 2024 | April 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18650675 | ANTIMICROBIAL COMPOSITION | April 2024 | July 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18646994 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | April 2024 | November 2025 | Allow | 19 | 1 | 1 | No | No |
| 18635375 | PYRAZINO[1',2':1,5]PYRAZOLO[4,3-B][1,6]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORS | April 2024 | July 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18594338 | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form | March 2024 | April 2025 | Allow | 14 | 0 | 1 | Yes | No |
| 18582522 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | February 2024 | September 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18438820 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS | February 2024 | October 2025 | Allow | 20 | 1 | 1 | No | No |
| 18437903 | 4,5-BIS(4-CHLOROPHENYL)-1-HEXYL-2-(3,4-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | February 2024 | April 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18431371 | 6'-(2-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUND | February 2024 | June 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18291712 | CRYSTALLINE FORMS | January 2024 | November 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 18413352 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | January 2024 | March 2025 | Allow | 14 | 0 | 1 | Yes | No |
| 18542159 | PYRAZINO[1',2':1,5]PYRAZOLO[4,3-B][1,6]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORS | December 2023 | March 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18527967 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | December 2023 | May 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18509742 | 2-(1-(2-HYDROXYPROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDINE AS AN ANTICANCER COMPOUND | November 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18388103 | 4,5-BIS(4-CHLOROPHENYL)-1-HEXYL-2-(3,4-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | November 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18386549 | 6'-(2-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUND | November 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18385989 | 6'-(3-BROMOPHENYL)-2'-METHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUND | November 2023 | January 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18498989 | 6'-(4-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT | October 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18493017 | 1-Methyl-4-[(4-Phenylphenyl)Sulfonylmethyl]Cyclohexyanol And 1-Methyl-4-[[4-(2-Pyridyl)Phenyl]Sulfonylmethyl]Cyclohexanol Compounds and Their Therapeutic Use | October 2023 | December 2024 | Allow | 13 | 0 | 1 | No | No |
| 18484798 | COMPOSITIONS FOR THE TREATMENT OF BLEPHARITIS | October 2023 | May 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18484384 | 4-(4-BROMOPHENYL)-2- ALKYLOXY-6-(2-OXO-2H-1-BENZOPYRAN-3-YL)PYRIDINE-3-CARBONITRILE AS ANTIMICROBIAL COMPOUNDS | October 2023 | January 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18372395 | 7-(4-((5-(4-CHLOROBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)IPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUND | September 2023 | November 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18367760 | Compounds and Methods for Inhibiting CYP26 Enzymes | September 2023 | January 2025 | Allow | 16 | 0 | 1 | Yes | No |
| 18242152 | 5-SUBSTITUTED AMINOPYRIMIDO[6',1':2,3]IMIDAZO[4,5-C][1,6]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORS | September 2023 | December 2023 | Allow | 3 | 0 | 1 | Yes | No |
| 18238425 | 2-(1-(2-HYDROXYPROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDINE AS AN ANTICANCER COMPOUND | August 2023 | July 2024 | Abandon | 11 | 2 | 0 | Yes | No |
| 18264061 | SALT FORM AND CRYSTAL FORM OF PYRAZOLE SUBSTITUTED IMIDAZO[1,2- A]QUINOXALINE DERIVATIVE | August 2023 | February 2026 | Allow | 30 | 0 | 0 | Yes | No |
| 18361836 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | July 2023 | December 2025 | Abandon | 29 | 2 | 0 | No | No |
| 18361275 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | July 2023 | February 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18225925 | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form | July 2023 | February 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18225236 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | July 2023 | July 2024 | Abandon | 12 | 1 | 0 | Yes | No |
| 18355790 | METHODS OF TREATING FIBROSIS | July 2023 | September 2024 | Allow | 14 | 0 | 0 | No | No |
| 18219444 | SODIUM CHLORITE COMPOSITIONS WITH ENHANCED ANTI-MICROBIAL EFFICACY AND REDUCED TOXICITY | July 2023 | October 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18215077 | SELECTIVE 5-LO INHIBITORS FOR THE TREATMENT OF BRONCHIAL ASTHMA | June 2023 | August 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18339096 | ANTIMICROBIAL, DISINFECTING AND WOUND HEALING COMPOSITIONS AND METHODS FOR PRODUCING AND USING SAME | June 2023 | February 2026 | Allow | 31 | 2 | 0 | Yes | No |
| 18334611 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | June 2023 | April 2024 | Allow | 10 | 1 | 2 | Yes | No |
| 18136777 | INTRAVENOUS BACLOFEN FORMULATIONS AND TREATMENT METHODS | April 2023 | January 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18298122 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE | April 2023 | July 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18295009 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18029842 | Crystalline Forms of a Pharmaceutical Compound | March 2023 | June 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18128828 | SINGLE PROTEIN-ENCAPSULATED PHARMACEUTICS FOR ENHANCING THERAPEUTIC EFFECTS | March 2023 | January 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18120757 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING DISEASES | March 2023 | February 2025 | Allow | 23 | 1 | 1 | No | No |
| 18116593 | Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease | March 2023 | December 2024 | Allow | 21 | 1 | 1 | No | No |
| 18175030 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | February 2023 | October 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18168155 | OPIOID RECEPTOR MODULATORS | February 2023 | August 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 18018792 | NOVEL STIRIPENTOL DERIVATIVE AND USE THEREOF | January 2023 | October 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 18102474 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | January 2023 | February 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18006701 | NOVEL ORGANIC FUNGICIDE | January 2023 | February 2026 | Allow | 36 | 2 | 1 | Yes | No |
| 18094502 | Solid Forms of Substituted Benzoxaborole and Compositions Thereof | January 2023 | May 2024 | Allow | 16 | 0 | 0 | Yes | No |
| 18014770 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | January 2023 | July 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18094113 | SELECTIVE 5-LO INHIBITORS FOR THE TREATMENT OF BRONCHIAL ASTHMA | January 2023 | March 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18082570 | Compositions and Methods for Identifying and Treating Dystonia Disorders | December 2022 | November 2025 | Abandon | 35 | 2 | 1 | Yes | No |
| 18009236 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING A PERIODONTAL DISEASE OR DISLOCATED TRAUMATIC TOOTH | December 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17992457 | SOLID FORMS OF AN S1P-RECEPTOR MODULATOR | November 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17926892 | INHIBITORS OF CORONAVIRUS PROTEASE | November 2022 | December 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17924896 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | November 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17982454 | RESPONSIVE ELASTIC POLYMERS AND METHODS OF MAKING AND USING SAME | November 2022 | July 2025 | Allow | 32 | 1 | 1 | No | No |
| 17978818 | A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF | November 2022 | August 2024 | Allow | 21 | 0 | 1 | Yes | No |
| 17970577 | MEDICAMENT FOR TREATING HYPERTENSION | October 2022 | January 2025 | Abandon | 27 | 2 | 0 | No | No |
| 17920602 | USES OF APREMILAST | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17969235 | FOOD INGREDIENTS FROM STEVIA REBAUDIANA | October 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17935911 | DEPOT ADMINISTRATION OF ILOPERIDONE | September 2022 | August 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17907290 | ANTIMICROBIAL TUBULAR CONDUITS | September 2022 | June 2025 | Allow | 32 | 0 | 0 | No | No |
| 17913379 | NEW THERAPEUTIC USES OF COMPOUNDS | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17945299 | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF | September 2022 | September 2025 | Allow | 36 | 0 | 1 | Yes | No |
| 17943652 | NUTRITIONAL COMPOSITIONS AND INFANT FORMULA FOR PROMOTING DE NOVO MYEALINATION | September 2022 | May 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 17930218 | USE OF COMBINED INHALANT CANNABINOID THERAPY IN THE TREATMENT OF MIGRAINE | September 2022 | March 2024 | Abandon | 18 | 0 | 1 | No | No |
| 17930381 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | September 2022 | July 2025 | Allow | 34 | 1 | 1 | No | No |
| 17891351 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | August 2022 | May 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17884403 | LOW DOSE PRODUCT AND METHOD FOR TREATING DIARRHEA | August 2022 | May 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17798044 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | August 2022 | January 2026 | Abandon | 41 | 3 | 1 | No | Yes |
| 17758973 | NEAR-INFRARED EMITTING PORPHYRIN COMPOUND AND PREPARATION METHOD AND USE THEREOF | July 2022 | November 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17810805 | COMPOSITIONS OF BIOACTIVE FULVATE FRACTIONS AND USES THEREOF | July 2022 | May 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17790132 | PHARMACEUTICAL COMPOSITION COMPRISING 4-HEXYLRESORCINOL AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF BONE DISEASE | June 2022 | November 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17855501 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | June 2022 | November 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17853367 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | June 2022 | December 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17850198 | SOLID POLYMORPHS OF A FLNA-BINDING COMPOUND AND ITS HYDROCHLORIDE SALTS | June 2022 | April 2024 | Allow | 21 | 0 | 1 | Yes | No |
| 17844934 | ENHANCING PHOTOSTABILITY OF THIOPYRIDINONE COMPOUND WITHOUT THE USE OF UV FILTERS | June 2022 | January 2026 | Allow | 43 | 3 | 1 | Yes | No |
| 17842415 | Protease Inhibitors for Treatment of Coronavirus Infections | June 2022 | November 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17842493 | HYALURONIC ACID DERIVATIVE AND USE THEREOF | June 2022 | February 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17842475 | HYALURONIC ACID DERIVATIVE AND USE THEREOF | June 2022 | March 2026 | Abandon | 45 | 2 | 1 | No | No |
| 17757409 | COMPOSITION THAT PROMOTE PRO-RESOLVING MEDIATORS | June 2022 | March 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17784637 | USE OF (5R,7R,10R)-12,15-DIOXO-ALPHA-SELINENE IN THE PREPARATION OF DRUGS | June 2022 | September 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17835307 | METHOD OF TREATING MICROBIAL INFECTIONS | June 2022 | February 2026 | Allow | 44 | 4 | 0 | Yes | No |
| 17834127 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | June 2022 | November 2024 | Allow | 29 | 1 | 1 | No | No |
| 17833105 | PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINE | June 2022 | July 2024 | Allow | 25 | 0 | 1 | Yes | No |
| 17831863 | PHARMACEUTICAL COMPOSITION COMPRISING PDE9 INHIBITOR | June 2022 | April 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17828412 | SINGLE-INJECTION METHODS AND FORMULATIONS TO INDUCE AND CONTROL MULTIPLE OVARIAN FOLLICLES IN BOVINE, CAPRINE, OVINE, CAMELID AND OTHER FEMALE ANIMALS | May 2022 | February 2024 | Allow | 21 | 0 | 1 | Yes | No |
| 17829194 | NOVEL ENTERIC COMBINATION THERAPY | May 2022 | October 2025 | Abandon | 41 | 4 | 1 | No | Yes |
| 17744185 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | May 2022 | November 2025 | Allow | 42 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RICCI, CRAIG D.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RICCI, CRAIG D works in Art Unit 1611 and has examined 505 patent applications in our dataset. With an allowance rate of 65.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.
Examiner RICCI, CRAIG D's allowance rate of 65.3% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by RICCI, CRAIG D receive 2.18 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by RICCI, CRAIG D is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +49.1% benefit to allowance rate for applications examined by RICCI, CRAIG D. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.8% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 13.8% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 88.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 79.3% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 52.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.8% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.8% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.